APVO

$0.00

(

+0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Aptevo Therapeutics Inc

NASDAQ | APVO

1.63

USD

+$0.00

(

+0.00%

)

At Close (As of Oct 14, 2025)

$21.68M

Market Cap

0.0006

P/E Ratio

2680.54

EPS

$381.10

52 Week High

$1.32

52 Week Low

HEALTHCARE

Sector

APVO Chart

Recent Chart
Price Action

APVO Technicals

Tags:

APVO Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$352K
Total Revenue $0
Cost Of Revenue $352K
Costof Goods And Services Sold $352K
Operating Income -$25M
Selling General And Administrative $10M
Research And Development $14M
Operating Expenses $24M
Investment Income Net -
Net Interest Income -
Interest Income -
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $352K
Income Before Tax -$24M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$24M
Comprehensive Income Net Of Tax -
Ebit -$24M
Ebitda -$24M
Net Income -$24M

Revenue & Profitability

Earnings Performance

APVO Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $16M
Total Current Assets $11M
Cash And Cash Equivalents At Carrying Value $8.7M
Cash And Short Term Investments $8.7M
Inventory -
Current Net Receivables -
Total Non Current Assets $4.9M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments -
Short Term Investments -
Other Current Assets $1.9M
Other Non Current Assets -
Total Liabilities $11M
Total Current Liabilities $6.2M
Current Accounts Payable $3.1M
Deferred Revenue -
Current Debt -
Short Term Debt -
Total Non Current Liabilities $4.6M
Capital Lease Obligations $4.6M
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $4.6M
Other Current Liabilities $3.2M
Other Non Current Liabilities -
Total Shareholder Equity $4.8M
Treasury Stock -
Retained Earnings -$248M
Common Stock $84K
Common Stock Shares Outstanding $14K

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$24M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $352K
Capital Expenditures $0
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment -
Cashflow From Financing $16M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$24M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$352K
Total Revenue $0
Cost Of Revenue $352K
Costof Goods And Services Sold $352K
Operating Income -$25M
Selling General And Administrative $10M
Research And Development $14M
Operating Expenses $24M
Investment Income Net -
Net Interest Income -
Interest Income -
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $352K
Income Before Tax -$24M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$24M
Comprehensive Income Net Of Tax -
Ebit -$24M
Ebitda -$24M
Net Income -$24M

APVO News

APVO Profile

Aptevo Therapeutics Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Aptevo Therapeutics Inc. is a clinical-stage biotechnology firm headquartered in Seattle, Washington, specializing in the development of innovative immunotherapeutic candidates targeting various cancer types. The company's robust pipeline leverages its proprietary platform technologies to create next-generation therapies aimed at improving patient outcomes in oncology. With a commitment to advancing cancer treatment, Aptevo is strategically positioned to contribute to significant breakthroughs in the biopharmaceutical landscape.

VHAI
+66.66%
$0.00
YYAI
-12.35%
$0.14
UGRO
+63.96%
$0.61
BURU
-20.87%
$0.40
BITF
+8.62%
$5.85
CGBS
-39.47%
$0.03
PLUG
+6.26%
$4.14
NVDA
-4.06%
$180.67
NVTS
+30.74%
$13.03
TMQ
+62.33%
$10.64
RGTI
+2.22%
$56.13
CAN
+21.05%
$1.84
LAES
+23.65%
$7.58
BYND
-23.22%
$0.79
JOBY
+7.30%
$17.99
SSKN
+43.83%
$2.21
DNN
+6.94%
$3.08
RR
+7.54%
$6.93
INTC
-3.77%
$35.81
ITP
+27.76%
$0.33
RXRX
+8.22%
$5.98
EDHL
+92.12%
$0.95
CRML
+28.00%
$29.80
F
+1.29%
$11.69
NAK
+4.13%
$2.76
DVLT
+24.76%
$2.12
ACHR
+2.37%
$13.07
WULF
+9.43%
$15.32
IONZ
+10.43%
$2.54
AXDX
-61.36%
$0.03
TLRY
-5.02%
$1.60
SOUN
+8.73%
$20.81
MNTS
+22.37%
$1.75
TSLA
-1.75%
$428.25
MARA
+10.25%
$22.31
BBD
+2.06%
$3.15
GPUS
-6.30%
$0.40
ETHD
+6.45%
$3.54
AMD
+3.10%
$223.14
SOFI
+2.22%
$27.74
QBTS
+10.06%
$44.71
ERIC
+20.62%
$9.85
CIFR
+1.47%
$20.64
BTBT
+6.38%
$4.00
AAL
+4.04%
$12.21
NUAI
+28.93%
$3.03
UUUU
+11.40%
$26.48
RIG
-2.34%
$3.12
CLF
+2.13%
$14.12
UAMY
+7.06%
$17.89
IREN
+8.16%
$69.37
AREC
+28.21%
$6.38
ADAP
-11.21%
$0.15
KDLY
-1.56%
$0.85
PLTR
+1.29%
$179.50
NIO
-4.45%
$6.86
APLD
+2.87%
$35.22
USAR
-2.72%
$37.62
JDZG
+55.32%
$2.92
CLSK
+11.89%
$22.42
EOSE
+23.37%
$17.05
WWR
+36.71%
$3.50
BTG
+0.21%
$5.32
ASST
-5.60%
$1.01
ABAT
+17.00%
$10.78
RMBL
+60.50%
$3.21
RF
+2.84%
$25.25
QUBT
+7.43%
$23.05
AMZN
-1.69%
$216.34
NOK
+4.28%
$5.47
ADD
-25.47%
$0.05
MP
+3.34%
$98.23
SNAP
-1.38%
$7.93
BMNR
-6.06%
$53.40
SRM
+53.27%
$10.30
BCRX
-8.59%
$6.43
ONDS
-4.81%
$10.29
PFE
-0.89%
$24.50
QS
-0.64%
$16.88
AQMS
+236.22%
$33.31
JBLU
+7.83%
$4.90
BAC
+2.37%
$50.02
RGTZ
-4.94%
$8.84
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
SLB
+1.73%
$32.27
GWH
-17.07%
$7.50
NAKA
-6.57%
$0.80
DFLI
-2.50%
$1.53
WLGS
-5.57%
$0.04
WFC
+7.46%
$84.81
T
+1.69%
$26.02
ABEV
+0.93%
$2.16
HPE
+1.81%
$25.24
ETWO
0.00%
$3.30
BULL
-0.59%
$11.67
NB
+4.94%
$11.88
GDXD
+3.93%
$0.76
VALE
-0.13%
$10.99
GWAV
+110.10%
$17.88
VHAI
+66.66%
$0.00
YYAI
-12.35%
$0.14
UGRO
+63.96%
$0.61
BURU
-20.87%
$0.40
BITF
+8.62%
$5.85
CGBS
-39.47%
$0.03
PLUG
+6.26%
$4.14
NVDA
-4.06%
$180.67
NVTS
+30.74%
$13.03
TMQ
+62.33%
$10.64
RGTI
+2.22%
$56.13
CAN
+21.05%
$1.84
LAES
+23.65%
$7.58
BYND
-23.22%
$0.79
JOBY
+7.30%
$17.99
SSKN
+43.83%
$2.21
DNN
+6.94%
$3.08
RR
+7.54%
$6.93
INTC
-3.77%
$35.81
ITP
+27.76%
$0.33
RXRX
+8.22%
$5.98
EDHL
+92.12%
$0.95
CRML
+28.00%
$29.80
F
+1.29%
$11.69
NAK
+4.13%
$2.76
DVLT
+24.76%
$2.12
ACHR
+2.37%
$13.07
WULF
+9.43%
$15.32
IONZ
+10.43%
$2.54
AXDX
-61.36%
$0.03
TLRY
-5.02%
$1.60
SOUN
+8.73%
$20.81
MNTS
+22.37%
$1.75
TSLA
-1.75%
$428.25
MARA
+10.25%
$22.31
BBD
+2.06%
$3.15
GPUS
-6.30%
$0.40
ETHD
+6.45%
$3.54
AMD
+3.10%
$223.14
SOFI
+2.22%
$27.74
QBTS
+10.06%
$44.71
ERIC
+20.62%
$9.85
CIFR
+1.47%
$20.64
BTBT
+6.38%
$4.00
AAL
+4.04%
$12.21
NUAI
+28.93%
$3.03
UUUU
+11.40%
$26.48
RIG
-2.34%
$3.12
CLF
+2.13%
$14.12
UAMY
+7.06%
$17.89
IREN
+8.16%
$69.37
AREC
+28.21%
$6.38
ADAP
-11.21%
$0.15
KDLY
-1.56%
$0.85
PLTR
+1.29%
$179.50
NIO
-4.45%
$6.86
APLD
+2.87%
$35.22
USAR
-2.72%
$37.62
JDZG
+55.32%
$2.92
CLSK
+11.89%
$22.42
EOSE
+23.37%
$17.05
WWR
+36.71%
$3.50
BTG
+0.21%
$5.32
ASST
-5.60%
$1.01
ABAT
+17.00%
$10.78
RMBL
+60.50%
$3.21
RF
+2.84%
$25.25
QUBT
+7.43%
$23.05
AMZN
-1.69%
$216.34
NOK
+4.28%
$5.47
ADD
-25.47%
$0.05
MP
+3.34%
$98.23
SNAP
-1.38%
$7.93
BMNR
-6.06%
$53.40
SRM
+53.27%
$10.30
BCRX
-8.59%
$6.43
ONDS
-4.81%
$10.29
PFE
-0.89%
$24.50
QS
-0.64%
$16.88
AQMS
+236.22%
$33.31
JBLU
+7.83%
$4.90
BAC
+2.37%
$50.02
RGTZ
-4.94%
$8.84
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
SLB
+1.73%
$32.27
GWH
-17.07%
$7.50
NAKA
-6.57%
$0.80
DFLI
-2.50%
$1.53
WLGS
-5.57%
$0.04
WFC
+7.46%
$84.81
T
+1.69%
$26.02
ABEV
+0.93%
$2.16
HPE
+1.81%
$25.24
ETWO
0.00%
$3.30
BULL
-0.59%
$11.67
NB
+4.94%
$11.88
GDXD
+3.93%
$0.76
VALE
-0.13%
$10.99
GWAV
+110.10%
$17.88
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.